IPO – Talk Bio

Three-Month Drought in U.S. Biotech IPOs: Recent Developments and Context

3 weeks ago talkbio0Tagged Droughts, IPO, Market, stocks

biotech IPO; biotech market; IPO drought; 2025; biotech fundraising; biotech stocks

Chronic care startup Omada Health files to go public

4 weeks ago talkbio0Tagged Administration occupational activities, cardiometabolic, Chronic Care Management, Diabetes, digital health, Health, Hinge Health, Hypertensive disease, IPO, musculoskeletal conditions, revenue growth, virtual care

Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

2 months ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

Alcon Secures Control of Aurion Biotech in Strategic Takeover

2 months ago talkbio0Tagged Alcon, AURN001, biotech, Bovichtus, Cell Therapy, CEO, corneal endothelial disease, IPO, stake, Surgical Replantation

Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute

Legal Battle Erupts as Deerfield Accuses Alcon of Obstructing Aurion Biotech’s IPO Plans

3 months ago talkbio0Tagged Alcon, biotech, biotech industry, Bovichtus, Chancery, Corporate, court, Deerfield Management, Delaware, governance, IPO, Legal, Public Offering, research, shareholder

Aurion Biotech, Alcon Research, Deerfield Management , Initial Public Offering (IPO), Legal dispute, Biotech industry, Corporate governance, Shareholder rights, Delaware Court of Chancery